etidronate has been researched along with Kidney Diseases in 11 studies
Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.
etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral etidronate has been used for 3 weeks, after failure of classical treatment." | 5.34 | [Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis]. ( Bottu, J; Trullemans, B; Van Nieuwenhuyse, JP, 2007) |
| " Serum samples were obtained for 72 h after dosing, and urine samples were collected for 72 h after dosing and then periodically for 6 weeks." | 2.69 | Effect of renal function on risedronate pharmacokinetics after a single oral dose. ( Eusebio, RA; Kelly, SC; Mitchell, DY; Nesbitt, JD; Pallone, KA; Powell, JH; Russell, DA; St Peter, JV; Thompson, GA, 2000) |
| "The data on gastrointestinal side effects (47 trials) indicated that alendronate, risedronate etidronate, and zolendronate have similar rates of the adverse effects; application of Bayesian network meta-analysis showed that equivalence was demonstrated according to margins around ±10%." | 2.52 | Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference. ( Fadda, V; Maratea, D; Messori, A; Trippoli, S, 2015) |
| "Oral etidronate has been used for 3 weeks, after failure of classical treatment." | 1.34 | [Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis]. ( Bottu, J; Trullemans, B; Van Nieuwenhuyse, JP, 2007) |
| "We studied the bone resorption state in GC-treated CKD patients and the effects of bisphosphonate on S-NTX." | 1.33 | Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease. ( Fujii, N; Hamano, T; Horio, M; Imai, E; Isaka, Y; Ito, T; Moriyama, T; Nagasawa, Y; Okada, N, 2006) |
| "The latter ones involved oxaluria (28 children), uraturia (17 children), cystinuria (14 children), and phosphaturia (9 children)." | 1.28 | [Use of xidifon for prevention and treatment of nephropathies with metabolic disorders in children]. ( Dunaeva, IP; Gavriushova, LP; Iur'eva, EA; Korovina, NA; Kulakova, GI; Mumladze, EB; Rzhevskaia, ON; Tvorogova, TM, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fadda, V | 1 |
| Maratea, D | 1 |
| Trippoli, S | 1 |
| Messori, A | 1 |
| Mori, H | 1 |
| Okada, Y | 1 |
| Tanaka, Y | 1 |
| Hashimoto, O | 1 |
| Hamano, T | 2 |
| Fujii, N | 2 |
| Nagasawa, Y | 2 |
| Isaka, Y | 2 |
| Moriyama, T | 2 |
| Okada, N | 1 |
| Imai, E | 2 |
| Horio, M | 2 |
| Ito, T | 2 |
| Mikami, S | 1 |
| Hori, M | 1 |
| Trullemans, B | 1 |
| Bottu, J | 1 |
| Van Nieuwenhuyse, JP | 1 |
| Fogelman, I | 1 |
| Bessent, R | 1 |
| Scullion, JE | 1 |
| Cuthbert, GF | 1 |
| Mitchell, DY | 1 |
| St Peter, JV | 1 |
| Eusebio, RA | 1 |
| Pallone, KA | 1 |
| Kelly, SC | 1 |
| Russell, DA | 1 |
| Nesbitt, JD | 1 |
| Thompson, GA | 1 |
| Powell, JH | 1 |
| Russell, RG | 1 |
| Fleisch, H | 1 |
| Korovina, NA | 1 |
| Gavriushova, LP | 1 |
| Iur'eva, EA | 1 |
| Rzhevskaia, ON | 1 |
| Mumladze, EB | 1 |
| Tvorogova, TM | 1 |
| Kulakova, GI | 1 |
| Dunaeva, IP | 1 |
| Molloi, S | 1 |
| Mazess, R | 1 |
| Bendsen, H | 1 |
| Wilson, M | 1 |
| Martinez, AB | 1 |
| Mandalunis, PM | 1 |
| Bozal, CB | 1 |
| Cabrini, RL | 1 |
| Ubios, AM | 1 |
3 reviews available for etidronate and Kidney Diseases
| Article | Year |
|---|---|
Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointesti | 2015 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Bisphosphonates treatment for chronic kidney disease-mineral and bone disorder].
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Chronic Disease; Diphosphonates; Etidron | 2012 |
Pyrophosphate and diphosphonates in skeletal metabolism. Physiological, clinical and therapeutic aspects.
Topics: Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Calcinosis; Calcium; Calcium M | 1975 |
2 trials available for etidronate and Kidney Diseases
| Article | Year |
|---|---|
Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).
Topics: Adult; Bone Density Conservation Agents; Bone Resorption; Chronic Disease; Drug Therapy, Combination | 2007 |
Effect of renal function on risedronate pharmacokinetics after a single oral dose.
Topics: Administration, Oral; Aged; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Kidney; Kidney | 2000 |
6 other studies available for etidronate and Kidney Diseases
| Article | Year |
|---|---|
Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Body Mass Index; Bone Density; Bone Density | 2006 |
[Etidronate per os in subcutaneous fat necrosis with hypercalcemia and nephrocalcinosis].
Topics: Adipose Tissue; Calcinosis; Etidronic Acid; Female; Humans; Hypercalcemia; Infant; Kidney Diseases; | 2007 |
Accuracy of 24-h whole-body (skeletal) retention of diphosphonate measurements.
Topics: Adult; Aged; Bone and Bones; Bone Diseases, Metabolic; Etidronic Acid; Female; Fractures, Bone; Huma | 1982 |
[Use of xidifon for prevention and treatment of nephropathies with metabolic disorders in children].
Topics: Adolescent; Calcium Metabolism Disorders; Child; Child, Preschool; Cystinuria; Diphosphonates; Etidr | 1990 |
Whole body and regional retention of Tc-99m-labeled diphosphonates with a whole-body counter: a study with normal males.
Topics: Bone and Bones; Bone Diseases; Etidronic Acid; Humans; Kidney Diseases; Male; Organotechnetium Compo | 1989 |
Renal function in mice poisoned with oral uranium and treated with ethane-1-hydroxy-1,1-bisphosphonate (EHBP).
Topics: Administration, Cutaneous; Administration, Oral; Animals; Creatinine; Diphosphonates; Kidney; Kidney | 2003 |